Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Current applications of multiparameter flow cytometry in plasma cell disorders

T. Jelinek, R. Bezdekova, M. Zatopkova, L. Burgos, M. Simicek, T. Sevcikova, B. Paiva, R. Hajek,

. 2017 ; 7 (10) : e617. [pub] 20171020

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc18024546

Grantová podpora
NV17-30089A MZ0 CEP - Centrální evidence projektů

Multiparameter flow cytometry (MFC) has become standard in the management of patients with plasma cell (PC) dyscrasias, and could be considered mandatory in specific areas of routine clinical practice. It plays a significant role during the differential diagnostic work-up because of its fast and conclusive readout of PC clonality, and simultaneously provides prognostic information in most monoclonal gammopathies. Recent advances in the treatment and outcomes of multiple myeloma led to the implementation of new response criteria, including minimal residual disease (MRD) status as one of the most relevant clinical endpoints with the potential to act as surrogate for survival. Recent technical progress led to the development of next-generation flow (NGF) cytometry that represents a validated, highly sensitive, cost-effective and widely available technique for standardized MRD evaluation, which also could be used for the detection of circulating tumor cells. Here we review current applications of MFC and NGF in most PC disorders including the less frequent solitary plasmocytoma, light-chain amyloidosis or Waldenström macroglobulinemia.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18024546
003      
CZ-PrNML
005      
20180713102314.0
007      
ta
008      
180709s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1038/bcj.2017.90 $2 doi
035    __
$a (PubMed)29053157
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Jelinek, T $u Department of Haematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. Faculty of Science, University of Ostrava, Ostrava, Czech Republic. Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, Pamplona, Spain.
245    10
$a Current applications of multiparameter flow cytometry in plasma cell disorders / $c T. Jelinek, R. Bezdekova, M. Zatopkova, L. Burgos, M. Simicek, T. Sevcikova, B. Paiva, R. Hajek,
520    9_
$a Multiparameter flow cytometry (MFC) has become standard in the management of patients with plasma cell (PC) dyscrasias, and could be considered mandatory in specific areas of routine clinical practice. It plays a significant role during the differential diagnostic work-up because of its fast and conclusive readout of PC clonality, and simultaneously provides prognostic information in most monoclonal gammopathies. Recent advances in the treatment and outcomes of multiple myeloma led to the implementation of new response criteria, including minimal residual disease (MRD) status as one of the most relevant clinical endpoints with the potential to act as surrogate for survival. Recent technical progress led to the development of next-generation flow (NGF) cytometry that represents a validated, highly sensitive, cost-effective and widely available technique for standardized MRD evaluation, which also could be used for the detection of circulating tumor cells. Here we review current applications of MFC and NGF in most PC disorders including the less frequent solitary plasmocytoma, light-chain amyloidosis or Waldenström macroglobulinemia.
650    _2
$a průtoková cytometrie $x metody $7 D005434
650    _2
$a lidé $7 D006801
650    _2
$a paraproteinemie $x diagnostické zobrazování $x patologie $7 D010265
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Bezdekova, R $u Department of Clinical Haematology, University Hospital Brno, Brno, Czech Republic.
700    1_
$a Zatopkova, M $u Faculty of Science, University of Ostrava, Ostrava, Czech Republic.
700    1_
$a Burgos, L $u Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, Pamplona, Spain.
700    1_
$a Simicek, M $u Faculty of Science, University of Ostrava, Ostrava, Czech Republic.
700    1_
$a Sevcikova, T $u Faculty of Science, University of Ostrava, Ostrava, Czech Republic.
700    1_
$a Paiva, B $u Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, Pamplona, Spain.
700    1_
$a Hajek, R $u Department of Haematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic. Faculty of Science, University of Ostrava, Ostrava, Czech Republic.
773    0_
$w MED00187996 $t Blood cancer journal $x 2044-5385 $g Roč. 7, č. 10 (2017), s. e617
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29053157 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180713102608 $b ABA008
999    __
$a ok $b bmc $g 1316677 $s 1021467
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 7 $c 10 $d e617 $e 20171020 $i 2044-5385 $m Blood cancer journal $n Blood Cancer J $x MED00187996
GRA    __
$a NV17-30089A $p MZ0
LZP    __
$a Pubmed-20180709

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace